| Aug 19 |
Cue Biopharma, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 19 |
Cue Biopharma GAAP EPS of -$0.20 beats by $0.04, revenue of $2.66M beats by $1.37M
|
| Aug 19 |
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 14 |
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
|
| Jul 26 |
Cue Biopharma downsizes to focus on autoimmune pipeline
|
| Jul 25 |
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
|
| Jun 21 |
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
|
| Jun 4 |
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
|
| Jun 3 |
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
|
| May 30 |
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
|
